Le Lézard
Classified in: Health, Science and technology
Subject: CCA

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024


- Management to Hold Conference Call at 08:30 a.m. EDT -

TEL AVIV, Israel, March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S. markets open.

BioLineRx Ltd.

The Company will host a conference call at 08:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until March 28, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for?autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside. 

Learn more about who we are, what we do, and how we do it at?www.biolinerx.com, or on?Twitter?and?LinkedIn.? 

Contacts:

United States
John Lacey
BioLineRx
[email protected]

Israel
Moran Meir
LifeSci Advisors, LLC
[email protected]

Logo - https://mma.prnewswire.com/media/2154863/4165445/BioLineRx_Ltd_Logo.jpg

SOURCE BioLineRx Ltd


These press releases may also interest you

at 11:31
FLCCC Alliance Names Lynne Kristensen Senior Director, Communications
The FLCCC Alliance today announced Lynne Kristensen will step into the newly created senior director, communications role leading global public relations and media strategy for the organization. She will also oversee the FLCCC's new international...

at 11:26
For A Bright Future Foundation Congratulates Gina Rogoto on Promotion to Senior Vice President of Programs and Operations
Louis Hernandez Jr., Founder and Chairman of the Board of the Foundation, proudly announces the promotion of Gina Rogoto to the position of Senior Vice President of Programs and Operations at Louis Hernandez Jr.'s Foundation For A Bright Future ("For...

at 11:25
Compensation satisfaction: Survey shows nurses' perception of fair pay on the decline
Medical Solutions, which connects nurses and allied health clinicians with hospitals and healthcare systems, has released findings from its annual Voices of Care survey. One key finding reveals that only 42.8% of respondents feel they are paid fairly...

at 11:18
Inside information: Alan Donze has been appointed as Bioretec's new CEO
Bioretec Ltd is pleased to announce that Mr. Alan Donze has been appointed CEO of Bioretec as of today, 20 May 2024. He will start in this position immediately. With a distinguished career spanning the banking and medical device industries, Mr. Donze...

at 11:16
POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCMtm AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL
Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing that OCMtm wound matrix alone...

at 11:10
BayCare Expands Graduate Medical Education to Include Surgery Residency Program
As part of its plan to bring more doctors to West Central Florida, the region's top health care system today announced that it will soon launch BayCare Health System's first surgery residency program. The Accreditation Council for Graduate Medical...

More news about Health...


News published on and distributed by: